Conference report highlights new research into drug delivery to treat eye diseaseNovember 18, 2008Group explores alternatives to surgery and intravitreous injection Rockville, MD - Researchers are investigating microneedles, nanoparticles and polymer carriers as potential new techniques to combat the leading cause of visual impairment and blindness in the United States, according to a report from the Third Annual ARVO/Pfizer Ophthalmics Research Institute Conference. The report (http://www.iovs.org/cgi/content/full/49/11/4712) includes summaries from seven sessions on techniques for ocular drug delivery to the posterior segment of the eye and includes the findings of and opinions of more than 30 top ophthalmic researchers, brought together by the ARVO Foundation for Eye Research. The article in the November issue of Investigative Opthalmology & Visual Science defines the current research and the future needs for ocular drug delivery.
Diseases of the posterior segment of the eye are responsible for the majority of visual impairment and blindness cases in the United States, according to George Williams, MD. Until recently, these diseases were primarily treated with surgery, but recent developments in drug therapies have either replaced or complemented surgery. But the challenge lies in delivering the drugs. Topical delivery such as ointments and drops are fairly ineffective, and delivery via intravitreous injection (an injection into the fluid in the behind the lens in the eye) can be hard on the patient. According to the report, "Improved drug delivery technologies that provide optimal pharmacokinetics, dose intervals and less invasive routes of administration are needed." During the two-day event, John Heckenlively, MD, joined Jayakrishna Ambarti, MD, in a session on animal models of posterior ocular diseases. Allan Hoffman, ScD, discussed the design of polymer carriers for intracellular delivery of biomolecular drugs, such as peptides, proteins and nucleic acid drugs. His group is focused on using a family of acid-sensitive polymers to help deliver one of the latest drugs, silencing RNA (siRNA). Another group of presenters discussed the use of nanoparticles, microbeads and microneedles. Mansoor M. Amiji, PhD, said that nanoparticles can help overcome barriers to drug delivery from the organ level to the subcellular level. Another research laboratory was investigating the effectiveness of hollow and solid microneedles that penetrate only hundreds of micrometers into the cornea or sclera to deliver drugs. A safer alternative to direct intravitreous injections might be transscleral delivery into the vitreous using subconjunctival injections, said Michael Robinson, MD, adding that researchers needed a clear understanding of the dynamic barriers for the technique to work in treating retinal diseases. Another researcher in this area, Dayle H. Geroski, PhD, suggested that the relatively high permeability of the sclera offers great potential for transscleral drug delivery, especially for administration to the posterior part of the eye. Other research focused on photodynamic therapy, which uses a photosensitizer agent that localizes more or less selectively to the target tissue and is activated by light, triggering chemical reactions that injure the target tissue. Association for Research in Vision and Ophthalmology Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size. Liver Injury Paleontology Amazon rainforest Coronary Heart Disease Uterine Fibroids Spinal Cord Memory loss Children Pancreatic Cancer Drugs Beta Cells Pheromone Fishing Robotic Surgery Brain Damage Testosterone Stomach Cancer Parasite Virtual Reality Body Image Dementia Insomnia Gravitational Wave Insulin Resistance Bullying
See More: Science News Tags | |||||||||||||||||||||
|
Related Eye Disease Current Events and Eye Disease News Articles U finds treatment that significantly slows progression of eye damage in persons with type 1 diabetes University of Minnesota Medical School researcher Michael Mauer, M.D., has found a treatment that significantly slows the progression of eye injury in people with type 1 diabetes, a common complication caused by this disease. 'Nature' and 'nurture' variables early predictors of AMD Like many diseases, causes for age-related macular degeneration (AMD) can be categorized as either "nature" or "nurture". New supplement may help slow sight loss in elderly Queen's University Belfast academics have helped develop an antioxidant supplement which may slow down sight loss in elderly people. Omega-3 fatty acids appear to impact AMD progression Omega-3 fatty acids found in fatty fish such as tuna and salmon may protect against progression of age-related macular degeneration (AMD), but the benefits appear to depend on the stage of disease and whether certain supplements are taken. Sight for sore eyes In a world-first breakthrough, University of New South Wales (UNSW) medical researchers have used stem cells cultured on a simple contact lens to restore sight to sufferers of blinding corneal disease. Old diabetes drug teaches experts new tricks Research from the Johns Hopkins Children's Center reveals that the drug most commonly used in type 2 diabetics who don't need insulin works on a much more basic level than once thought, treating persistently elevated blood sugar - the hallmark of type 2 diabetes - by regulating the genes that control its production. Type of vitamin B1 could treat common cause of blindness University of Texas Medical Branch at Galveston researchers have discovered that a form of vitamin B1 could become a new and effective treatment for one of the world's leading causes of blindness. Study reports success in treating a rare retinal disorder Patients with a rare, blinding eye disease saw their vision improve after treatment with drugs to suppress their immune systems, according to researchers at the University of Michigan Kellogg Eye Center. Study reports success in treating a rare retinal disorder Patients with a rare, blinding eye disease saw their vision improve after treatment with drugs to suppress their immune systems. Stem cell therapy makes cloudy corneas clear, according to Pitt researchers Stem cells collected from human corneas restore transparency and don't trigger a rejection response when injected into eyes that are scarred and hazy, according to experiments conducted in mice by researchers at the University of Pittsburgh School of Medicine. More Eye Disease Current Events and Eye Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||